YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Enhancement of TRAIL-Induced Apoptosis in Human Hepatocellular Carcinoma Cells by Apigenin

인체 간암세포에서 Apigenin에 의한 TRAIL 유도 Apoptosis의 증진 효과

  • Kim, Eun-Young (College of Pharmacy, Sookmyung Women's University) ;
  • Kim, An-Keun (College of Pharmacy, Sookmyung Women's University)
  • 김은영 (숙명여자대학교 약학대학) ;
  • 김안근 (숙명여자대학교 약학대학)
  • Received : 2010.12.10
  • Accepted : 2011.02.09
  • Published : 2011.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is one of the promising anti-cancer agent because of its ability to selectively induce apoptosis in tumor cell lines but not in normal cells. However, TRAIL resistance has been reported in some cancer cells including hepatocarcinoma cells. Therefore, studies of agents that sensitize TRAIL-resistant cancer cells could be a effective therapeutic approach in cancer management. In our study, we examined the effect of combination of TRAIL with apigenin in human hepatocellular carcinoma cells. As a result, the combined use of TRAIL and apigenin significantly enhanced the cytotoxicity in PLC-PRF5 cells. Flow cytometry analysis after annexin V-FITC/PI dual staining showed that this increase of cell cytotoxicity was related to enhanced apoptosis in combined treatment of TRAIL with apigenin. Furthermore, synergistic induction of apoptosis was also confirmed by observation of morphological changes and annexin V-FITC/PI fluorescence. Our findings suggests that apigenin has the potential to improve the efficiency of TRAIL-based therapies in human hepatocellular carcinoma cells. Further study is needed to reveal the molecular mechanisms of this combined therapy.

Keywords

References

  1. World Health Organization, Fact sheet 297. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/index.html.Accessed 2009.
  2. Ministry for Heath, Welfare and Family Affairs. Annual report of cancer incidence (2005) and survival (1993-2005) in Korea. (2008).
  3. Organization for Economic Co-operation and Development. Health at a Glance 2009: OECD indicators (2009).
  4. LeBlanc, H. N. and Ashkenazi, A. : Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10, 66 (2003). https://doi.org/10.1038/sj.cdd.4401187
  5. Sheikh, M. S. and Huang, Y. : Death receptors as targets of cancer therapeutics. Curr. Cancer Drug Targets 4, 97 (2004). https://doi.org/10.2174/1568009043481597
  6. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R. and Boyle, W. J. : Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309 (1997). https://doi.org/10.1016/S0092-8674(00)80209-3
  7. Holoch, P. A. and Griffith, T. S. : TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies. Eur. J. Pharmacol. 625, 63 (2009). https://doi.org/10.1016/j.ejphar.2009.06.066
  8. Oldenhuis, C., Stegehuis, J. H., Walenkamp, A. M. E., de Jong, S. and de Vries, E. G. E. : Targeting TRAIL death receptors. Curr. Opin. Pharmacol. 8, 433 (2008). https://doi.org/10.1016/j.coph.2008.06.011
  9. Huang, Y. and Sheikh, M. S. : TRAIL death receptors and cancer therapeutics. Toxicol. Appl. Pharm. 224, 284 (2007). https://doi.org/10.1016/j.taap.2006.12.007
  10. Griffith, T. S. and Lynch, D. H. : TRAIL: a molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. 10, 559 (1998). https://doi.org/10.1016/S0952-7915(98)80224-0
  11. Burns, T. F. and El-Deiry, W. S. : Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem. 276, 37879 (2001).
  12. Morgan, D. M. : Tetrazolium (MTT) assay for cellular viability and activity. Method. Mol. Biol. 79, 179 (1998).
  13. Vermes, I., Haanen, C., Steffens-Nakken, H. and Reutellingsperger, C. : A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184, 39 (1995). https://doi.org/10.1016/0022-1759(95)00072-I
  14. Hacker, G. : The morphology of apoptosis. Cell Tissue Res. 301, 5 (2000). https://doi.org/10.1007/s004410000193
  15. Van Cruchten, S. and Van Den Broeck, W. : Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat. Histol. Embryol. 31, 214 (2002). https://doi.org/10.1046/j.1439-0264.2002.00398.x
  16. Bossy-Wetzel, E. and Green, D. R. [2]Detection of apoptosis by annexin V labeling. Academic Press, City (2000).
  17. Shounan, Y., Feng, X. and O'Connell, P. J. : Apoptosis detection by annexin V binding: a novel method for the quantitation of cell-mediated cytotoxicity. J. Immunol. Methods 217, 61 (1998). https://doi.org/10.1016/S0022-1759(98)00090-8